Aptevo Therapeutics - Hyperimmune Commercial Products - Ownership and Business Overview

Medical ProductsCompany

Aptevo Therapeutics - Hyperimmune Commercial Products Ownership

Who owns Aptevo Therapeutics - Hyperimmune Commercial Products?

Aptevo Therapeutics - Hyperimmune Commercial Products is owned by Saol Therapeutics. It was acquired on August 31, 2017.

Aptevo Therapeutics - Hyperimmune Commercial Products Business Overview

Where is Aptevo Therapeutics - Hyperimmune Commercial Products headquartered?

Aptevo Therapeutics - Hyperimmune Commercial Products is headquartered in Seattle, Washington.

What sector is Aptevo Therapeutics - Hyperimmune Commercial Products in?

Aptevo Therapeutics - Hyperimmune Commercial Products is a medical products company.

Medical Products M&A Summary in 2017

Out of 60 sectors in the Mergr database, medical products ranked 13 in number of deals in 2017. The largest medical products acquisition in 2017 was C. R. Bard - which was acquired by Becton Dickinson for $24.0B.

Join Mergr to view all 208 acquisitions of medical products companies in 2017, including 26 acquisitions by private equity firms, and 182 by strategics.

Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products

Seattle, Washington 98101
United States,

Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products comprises WinRho SDF, HepaGam B, and VARIZIG. WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.


 Subscribe to unlock this and 201,649
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.